A Brave New World: Digital Health Redo | Boehringer Ingelheim US
Find out more on how digital innovation in Boehringer Ingelheim is transforming the world of animal health, including disease prevention and vaccination.
Search
Boehringer Ingelheim to unveil oncology research at WCLC
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Arising Vaccines to Help Zoo Elephants | Boehringer Ingelheim US
Find out how Boehringer Ingelheim is developing vaccines to help North African zoo elephants suffering from deadly infections and illness.
Partnering Culture
BI's long-term research and investment focus means we can work together to realize their ideas by fully committing to lasting relationships.
Newsletter Subscription Confirmation
Newsletter : Thank you for subscribing
Management Rotation | Academic Programs
Management Rotation Program
A grandmother’s empathy offers a safe space for people with mental health conditions
Supporting the Friendship Bench to improve access to mental healthcare.
Boehringer included on LinkedIn’s “Top Companies 2024” list
Investing in our people is at the core of what we do
Schizophrenia in real life: Stories of resilience and hope
Discover the reality of life with schizophrenia through the stories of four people who are breaking down the stigma of living with a serious mental illness.
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
Your Milestones Drive Ours
Learn more about the experiences of living with nonsmall cell lung cancer and cholangiocarcinoma as well as caring for a loved one during a cancer journey.
Targeting HER2 in cancer
Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.
More Health Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
The View from Both Sides of the Table
The View from Both Sides of the Table
Translating Human Pharma Science into Animal Health Innovation
Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health
Biberach
Click here to view our Biberach site, in Southern Germany, home to the largest research & development center within Boehringer Ingelheim’s global network.
U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes
U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes
Chronic Kidney Disease
Chronic Kidney Disease
Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease
Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease
Purchasing
Suppliers are an integral part of our success. We are passionate about solutions and new opportunities to review, improve and optimize our supplier base.
Our Curiosity Never Stops | Boehringer Ingelheim US
Hear from Dr. Cornelia Dorner-Ciossek on how brain research informs treatment methods for patients suffering with mental illnesses.
J-Code Issued for SPEVIGO
Boehringer Ingelheim receives permanent J-code for SPEVIGO, indicated for the treatment of generalized pustular psoriasis flares in adults
Open Innovation at Boehringer Ingelheim
Open Innovation at Boehringer Ingelheim
Regulatory Affairs
Read more on BI's two-year fellowship within Regulatory Affairs. The Fellow will obtain in-depth and hands-on experience in regulatory strategy.